

Resource Summary Report

Generated by [NIF](#) on Sep 22, 2026

SU-DHL-4

RRID:CVCL_0539

Type: Cell Line

Proper Citation

RRID:CVCL_0539

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0539

Proper Citation: RRID:CVCL_0539

Description: Cell line SU-DHL-4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: [PMID:83902](#), [PMID:177185](#), [PMID:214220](#), [PMID:371794](#), [PMID:2875799](#), [PMID:2985879](#), [PMID:3159941](#), [PMID:3874327](#), [PMID:3881165](#), [PMID:8547074](#), [PMID:8957066](#), [PMID:9738977](#), [PMID:9787181](#), [PMID:10739008](#), [PMID:11226526](#), [PMID:12169673](#), [PMID:17363600](#), [PMID:18357372](#), [PMID:19278952](#), [PMID:20054396](#), [PMID:20628145](#), [PMID:20889926](#), [PMID:22460905](#), [PMID:23292937](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25894527](#), [PMID:26589293](#), [PMID:26727417](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28356514](#), [PMID:29416618](#), [PMID:29666304](#), [PMID:30165192](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU-DHL-4

Synonyms: SUDHL4, Sudhl4, SUDHL-4, Sudhl-4, SuDHL 4, SUD-4, SUD4, SU4, Stanford University-Diffuse Histiocytic Lymphoma-4, DHL-4, DHL4

Cross References: BTO:BTO_0006462, CLO:CLO_0037061, EFO:EFO_0006492, MCCL:MCC:0000440, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-2957, BioGRID_ORCS_Cell_line:742, BioSample:SAMN03473232, BioSample:SAMN10988472, cancercellines:CVCL_0539, CCRID:3101HUMSCSP5048, Cell_Model_Passport:SIDM00405, ChEMBL-Cells:ChEMBL3308053, ChEMBL-Targets:ChEMBL613711, CLS:305106, Cosmic:850203, Cosmic:932763, Cosmic:999780, Cosmic:1067443, Cosmic:1079254, Cosmic:1517656, Cosmic:1541909, Cosmic:1636687, Cosmic:1714160, Cosmic:1945192, Cosmic:2276338, Cosmic:2361375, Cosmic:2437313, Cosmic-CLP:1331035, DepMap:ACH-000365, DSMZ:ACC-495, DSMZCellDive:ACC-495, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, ENCODE:ENCBS265MKB, ENCODE:ENCBS980NLV, GDSC:1331035, GEO:GSM274842, GEO:GSM380145, GEO:GSM499735, GEO:GSM552463, GEO:GSM562826, GEO:GSM887653, GEO:GSM888745, GEO:GSM1035322, GEO:GSM1374906, GEO:GSM1670485, IARC_TP53:25031, IARC_TP53:28236, ICLC:HTL10002, LiGeA:CCLE_386, LINCS_LDP:LCL-1136, Lonza:270, PharmacDB:SUDHL4_1502_2019, PRIDE:PXD000589, PRIDE:PXD030304, Progenetix:CVCL_0539, PubChem_Cell_line:CVCL_0539, Ubigen:YC-C082, Wikidata:Q54970717

ID: CVCL_0539

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260920T005902+0000

Ratings and Alerts

No rating or validation information has been found for SU-DHL-4.

Warning: Discontinued: ICLC; HTL10002

Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 60 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Demel UM, et al. (2026) Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(17), e11449.

Kunzmann GB, et al. (2026) Dynamic UFMylation governs cellular fitness by coordinating multi-organelle proteostasis. *bioRxiv : the preprint server for biology*.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. *Cell reports. Medicine*, 7(3), 102644.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. *Cancer cell*, 44(7), 1437.

Calaud C, et al. (2026) Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma. *Blood neoplasia*, 3(2), 100214.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. *iScience*, 28(5), 112333.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. *Blood cancer discovery*, 6(6), 580.

Peled A, et al. (2025) BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway. *Research square*.

Abdelhamed S, et al. (2025) PF-08046032: A Novel, Investigational CD25-Directed Antibody-Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors. *Molecular cancer therapeutics*, 24(7), 963.

Porazzi P, et al. (2025) EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. *Cancer cell*, 43(3), 537.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. *iScience*, 28(6), 112584.

Shi X, et al. (2025) NFS1, together with FXN, protects cells from ferroptosis and DNA damage in diffuse large B-cell lymphoma. *Redox biology*, 87, 103878.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. *Cell*, 188(2), 331.

Reversat A, et al. (2025) Mass Cytometry-Based Approach for the Investigation of Stimulator of Interferon Genes Pathway. *European journal of immunology*, 55(12), e70101.

McCrury M, et al. (2024) Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. *Molecular cancer therapeutics*, 23(3), 316.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. *Cancer cell*, 42(5), 833.

Layden HM, et al. (2024) Mutant FOXO1 controls an oncogenic network via enhancer accessibility. *Cell genomics*, 4(4), 100537.

Rane G, et al. (2024) ZBTB48 is a priming factor regulating B-cell-specific CIITA expression. *The EMBO journal*, 43(24), 6236.

Li J, et al. (2024) Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. *Nature communications*, 15(1), 2879.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. *Leukemia*, 38(10), 2210.